$69 postpage LB

Creso Pharma (ASX:CPH) anticipates game-changing TGA decision in December

  • November 27, 2020 03:31 PM AEDT
  • Team Kalkine
Creso Pharma (ASX:CPH) anticipates game-changing TGA decision in December

Summary

  • TGA’s final decision regarding a significant regulatory change for CBD products distribution in Australia is anticipated in December 2020.
  • Down-scheduling CBD products could lead to substantial market opportunities for Creso Pharma.
  • The Company is positioned well to capitalise in the market once TGA’s final decision is out.
Gold MTF non-AMP

Creso Pharma Limited (ASX:CPH) disclosed that the TGA’s final decision regarding a significant regulatory change for distribution of cannabidiol (CBD) products in Australia is anticipated in late December 2020. The regulatory amendment is related to down scheduling CBD products to schedule 3 medicine.

Creso Pharma said that there are several opportunities and potential new sales channels on the way for the Company. This news has buoyed the stock of Creso Pharma, helping the shares gain 9.375% to reach at A$0.035 on 27 November 2020 (at AEDT 3:26 PM). The Company’s market capitalisation stood at A$22.02 million.

Let us discuss in detail-

About Creso Pharma Limited

ASX-cannabis player Creso Pharma Limited brings the best of cannabis to better the lives of people as well as animals.  With its pharmaceutical expertise and methodological rigour, the Company engaged in the development of cannabis and hemp-derived products.

Image Source: © Kalkine Group 2020

Huge market opportunity on the cards of Creso Pharma

On 26 November 2020, Creso Pharma updated that the TGA’s decision concerning amendments for down scheduling cannabidiol products to schedule 3 medicine anticipated in December 2020.

The interim decision was made on 9 September 2020, and the final ruling will follow this. The interim decision recommended that in Australia, CBD products to be down scheduled from schedule 4 to schedule 3 medicines.

This down scheduling would allow Australians to purchase CBD products over-the-counter (OTC) at pharmacies without any prescription.

The CBD products down scheduling in the country creates a substantial market opportunity for Creso’s CBD and hemp products.

Notably, Creso Pharma remains well-funded for capitalising in the Australian market after the final decision by the TGA.

Creso Pharma’s cannaQIX® 50

Currently, Creso Pharma sells its cannaQIX® 50 in Australia as a medicinal cannabis product under the ‘LozaCan’ brand through its distribution partner BHC (Burleigh Heads Cannabis).

Moreover, the Company has developed a comprehensive range of CBD and hemp-oil products under the cannaQIX® brand, which it anticipates selling across Australia after any favourable decision.

The cannaQIX® product range is manufactured under GMP standards and offers consumers with a standardised formulation as well as precise measurement of dosage.

Non-Executive Chairman of Creso Pharma Adam Blumenthal commented-

ALSO READ: ASX small cap Creso Pharma (ASX:CPH) taps A$8.992m funding

 

 


Disclaimer
The website https://kalkinemedia.com/au is a service of Kalkine Media Pty. Ltd. (Kalkine Media) A.C.N. 629 651 672. The principal purpose of the content on this website is to provide factual information only and does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stock of the company (or companies) or engage in any investment activity under discussion. We are neither licensed nor qualified to provide investment advice through this platform. In providing you with the content on this website, we have not considered your objectives, financial situation or needs. You should make your own enquiries and obtain your own independent advice prior to making any financial decisions.
Some of the images that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed on this website unless stated otherwise. The images that may be used on this website are taken from various sources on the web and are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it below the image. The information provided on the website is in good faith, however Kalkine Media does not make any representation or warranty regarding the content, accuracy, or use of the content on the website.

 

   
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. OK